Health Professionals

Making Sense of Melanoma Adjuvant Treatment in the Absence of OS Data

We will finalize this series on where we should go, and what’s next in terms of immunotherapy in the adjuvant setting, by looking into the two other aspects that we need to consider when we discuss the factthat there is no overall survival benefit nor are there data on the overall survival benefit for patients treated with immunotherapy in the adjuvant setting.

Read More
MRV News
Melanoma News
Archive
Menu